Back
 JDM  Vol.2 No.4 , November 2012
Acute pancreatitis in a patient receiving sitagliptin
Abstract: Describing a reported case of acute pancreatitis in a patient receiving sitagliptin. We present the biochemical and findings of a 60 year-old male who presented with severe abdominal pain and was found to have acute pancreatitis. This occurred one month after the commencement of sitagliptin, a dipeptidyl peptidase IV inhibitor, for the treatment of uncontrolled type 2 diabetes. Results: Pancreatic enzymes were elevated (i.e. amylase 204, lipase: 525.3) with a normal liver function test and a normal lipid profile. Ultrasound abdomen was unremarkable. In the absence of an identifiable cause for the patient’s pancreatitis, sitagliptin was considered a potential trigger and on ceasing this agent, the patient recovered from his condition. Conclusion: Incretin-based therapy is an effective line in the treatment of type 2 diabetes mellitus. FDA issued a warning letters to the drug company because of emerging reports of acute pancreatitis in patients receiving sitagliptin. This is unfortunately not the first reported case of acute pancreatitis in a patient receiving sitagliptin and it supports the possibility that acute pancreatitis may be the effect of incretin-based therapy.
Cite this paper: Sanaseeri, S. , Almohaini, A. and Hashem, A. (2012) Acute pancreatitis in a patient receiving sitagliptin. Journal of Diabetes Mellitus, 2, 406-407. doi: 10.4236/jdm.2012.24063.
References

[1]   Aggio, L.L. and Drucker, D.J. (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology, 132, 213-2157.

[2]   Kieffer, T.J. and Habener, J.F. (1999) Theglucagon-like-peptides. Endocrine Reviews, 20, 876-913. doi:10.1210/er.20.6.876

[3]   Dalla, M.C., Bock, G., Giesler, P.D., Serra, D.B., LiguerosSaylan, M., Foley, J.E., Camilleri, M., Toffolo, G., Cobelli, C., Rizza, R.A. and Vella, A. (2009) Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes. Diabetes Care, 32, 14-18. doi:10.2337/dc08-1512

[4]   Olansky, L. (2010) “Do incretin-based therapies cause acute pancreatitis?” Journal of Diabetes Science and Technology, 4, 228-229.

[5]   Forsmark, C.E. and Baillie, J. (2007) AGA Institute Clinical Practice Economics Committee. AGA Institute Governing; Board AGA Institute Clinical Practice and Economics Committee; AGA Institute Governing Board. Gastroenterology, 132, 2022-2044. doi:10.1053/j.gastro.2007.03.065

[6]   Forsmark, C.E. and Baillie, J. (2007) AGA Institute Clinical Practice Economics Committee. AGA Institute Governing; Board AGA Institute Clinical Practice and Economics Committee; AGA Institute Governing Board. Gastroenterology, 132, 2022-2044. doi:10.1053/j.gastro.2007.03.065

[7]   Field, A.E., Coakley, E.H., Must, A., Spadano, J.L., Laird, N., Dietz, W.H., Rimm and E., Colditz, G.A. (2001) Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Archives of Internal Medicine, 161, 1581-1586. doi:10.1001/archinte.161.13.1581

[8]   Nachnani, J.S., Bulchandani, D.G., Nookala, A., et al. (2010) Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia, 53,153-159. doi:10.1007/s00125-009-1515-4

[9]   Matveyenko, A.V., Dry, S., Cox, H.I., et al. (2009) Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: Interactions with metformin. Diabetes, 58, 1604-1615. doi:10.2337/db09-0058

 
 
Top